Royalty Pharma plc Increase (Decrease) in Interest Payable, Net
Royalty Pharma plc (RPRX) reported Increase (Decrease) in Interest Payable, Net of -$3.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2026-08-05
- Royalty Pharma plc increase (decrease) in interest payable, net for the quarter ending 2026-06-30 was $82.46M, a 31.80% increase year-over-year.
- Royalty Pharma plc increase (decrease) in interest payable, net for the quarter ending 2026-03-31 was -$85.52M.
- Royalty Pharma plc increase (decrease) in interest payable, net for the quarter ending 2025-12-31 was $81.77M, a 37.09% increase year-over-year.
- Royalty Pharma plc increase (decrease) in interest payable, net for the quarter ending 2025-09-30 was -$56.56M.
- Royalty Pharma plc increase (decrease) in interest payable, net for fiscal 2025 was $8.93M, a 80.74% decline from fiscal 2024.
- Royalty Pharma plc increase (decrease) in interest payable, net for fiscal 2024 was $46.38M.
- Royalty Pharma plc increase (decrease) in interest payable, net for fiscal 2023 was -$2.48M.
- Royalty Pharma plc increase (decrease) in interest payable, net for fiscal 2022 was -$3.53M, a 122.73% decline from fiscal 2021.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 9 month | Increase (Decrease) in Interest Payable, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $82.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$3.05M 10-Q · filed 2026-08-05 | $78.72M derived: sum of 3 quarters · filed 2026-08-05 | $22.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$85.52M 10-Q · filed 2026-05-06 | -$3.74M derived: sum of 2 quarters · filed 2026-05-06 | -$60.31M derived: sum of 3 quarters · filed 2026-05-06 | $2.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $81.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $25.21M derived: sum of 2 quarters · filed 2026-02-11 | $87.78M derived: sum of 3 quarters · filed 2026-08-05 | $8.93M 10-K · filed 2026-02-11 |
| 2025-09-30 | -$56.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $6.00M derived: sum of 2 quarters · filed 2026-08-05 | -$72.84M 10-Q · filed 2025-11-05 | -$13.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $62.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$16.27M 10-Q · filed 2026-08-05 | $43.38M derived: sum of 3 quarters · filed 2026-08-05 | $25.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$78.84M 10-Q · filed 2026-05-06 | -$19.19M derived: sum of 2 quarters · filed 2026-05-06 | -$37.03M derived: sum of 3 quarters · filed 2026-05-06 | $6.63M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $59.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $41.81M derived: sum of 2 quarters · filed 2026-02-11 | $85.47M derived: sum of 3 quarters · filed 2026-02-11 | $46.38M 10-K · filed 2026-02-11 |
| 2024-09-30 | -$17.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $25.82M derived: sum of 2 quarters · filed 2025-11-05 | -$13.27M 10-Q · filed 2025-11-05 | $25.82M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $43.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $4.57M 10-Q · filed 2025-08-06 | $43.66M derived: sum of 3 quarters · filed 2026-02-11 | $2.09M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | -$39.09M 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | -$41.57M derived: sum of 3 quarters · filed 2026-02-11 | -$604.00K derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $39.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$2.48M derived: sum of 2 quarters · filed 2026-02-11 | $38.48M derived: sum of 3 quarters · filed 2026-02-11 | -$2.48M 10-K · filed 2026-02-11 |
| 2023-09-30 | -$41.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$604.00K derived: sum of 2 quarters · filed 2024-11-06 | -$41.57M 10-Q · filed 2024-11-06 | -$604.00K derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $40.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $40.96M derived: sum of 3 quarters · filed 2025-02-12 | $0.00 derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | -$40.96M 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | -$40.96M derived: sum of 3 quarters · filed 2025-02-12 | $0.00 derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $40.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | $40.96M derived: sum of 3 quarters · filed 2025-02-12 | -$3.53M 10-K · filed 2025-02-12 |
| 2022-09-30 | -$40.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | -$44.50M 10-Q · filed 2023-11-08 | -$3.53M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $40.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$3.53M 10-Q · filed 2023-08-08 | $37.43M derived: sum of 3 quarters · filed 2024-02-15 | $11.26M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$44.50M 10-Q · filed 2023-05-09 | -$3.53M derived: sum of 2 quarters · filed 2024-02-15 | -$29.70M derived: sum of 3 quarters · filed 2024-02-15 | $2.93M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $40.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $14.79M derived: sum of 2 quarters · filed 2024-02-15 | $47.42M derived: sum of 3 quarters · filed 2024-02-15 | $15.55M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$26.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $6.46M derived: sum of 2 quarters · filed 2022-11-08 | -$25.41M 10-Q · filed 2022-11-08 | $16.73M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $32.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $758.00K 10-Q · filed 2022-08-04 | $42.90M derived: sum of 3 quarters · filed 2023-02-15 | $42.90M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | -$31.88M 10-Q · filed 2022-05-05 | $10.27M derived: sum of 2 quarters · filed 2023-02-15 | $10.27M derived: sum of 3 quarters · filed 2023-02-15 | $10.27M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $42.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $42.15M derived: sum of 2 quarters · filed 2023-02-15 | $42.15M derived: sum of 3 quarters · filed 2023-02-15 | $42.15M 10-K · filed 2023-02-15 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $0.00 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-15 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |